Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets
By
Ahmed Hassan
Amr Yosry Emam
Mina Samir
Kerolos Sobhy
Ihab Abd El Nabi
Hala Ali
Mohammed Thabet
Ahmed Elghazoly
Nagwa Thabet
Ahmed Elguindy
May 29, 2026
Clinical Scorecard: Post-STEMI Inflammatory Risk: Common Occurrence Despite LDL-C Management and Links to Secondary Prevention Goals
At a Glance
Category Detail
Condition Residual inflammatory risk after ST-elevation myocardial infarction (STEMI) Key Mechanisms High-sensitivity C-reactive protein (hs-CRP) as a marker of inflammation Target Population Patients post-primary percutaneous coronary intervention (pPCI) for STEMI Care Setting Cardiovascular follow-up care
Key Highlights
44.6% of patients had elevated hs-CRP levels (>3 mg/L) 29.8% of patients with LDL-C < 55 mg/dL still exhibited elevated hs-CRP Achieving secondary prevention targets correlates with lower hs-CRP levels Comprehensive secondary prevention includes lipid management and medication adherence Guideline-Based Recommendations
Diagnosis
Use hs-CRP to assess residual inflammatory risk post-STEMI Management
Focus on achieving LDL-C < 55 mg/dL, waist circumference reduction, and medication adherence Monitoring & Follow-up
Regular assessment of hs-CRP levels and secondary prevention metrics Risks
Persistent inflammatory risk despite optimal LDL-C management Patient & Prescribing Data
878 patients who underwent pPCI for STEMI
Statin and ACEI/ARB therapy adherence associated with lower hs-CRP
Clinical Best Practices
Implement comprehensive secondary prevention strategies Monitor hs-CRP levels alongside traditional risk factors Encourage lifestyle modifications for cardiovascular risk reduction Related Resources & Content
